GERI-BP001化合物，烟曲霉F37酰基辅酶A：胆固醇酰基转移酶的新型抑制剂。I. 生产、分离以及物理化学和生物学特性

GERI-BP001 compounds, new inhibitors of acyl-CoA: cholesterol acyltransferase from Aspergillus fumigatus F37. I. Production, isolation, and physico-chemical and biological properties.

作者信息

Jeong T S, Kim S U, Son K H, Kwon B M, Kim Y K, Choi M U, Bok S H

机构信息

Bioproducts Research Group, Korea Research Institute of Bioscience & Biotechnology, KIST, Taejon.

出版信息

J Antibiot (Tokyo). 1995 Aug;48(8):751-6. doi: 10.7164/antibiotics.48.751.

DOI:10.7164/antibiotics.48.751

PMID:7592016

Abstract

GERI-BP001 compounds, new inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT), were isolated from a culture broth of Aspergillus fumigatus F37 by acetone extraction, EtOAc extraction, SiO2 column chromatography, and reverse phase HPLC. GERI-BP001 M, A, and B inhibit ACAT activity in an enzyme assay system using rat liver microsomes by 50% at concentrations of 42, 94, and 40 microM, respectively.

摘要

GERI - BP001化合物是酰基辅酶A：胆固醇酰基转移酶（ACAT）的新型抑制剂，通过丙酮萃取、乙酸乙酯萃取、硅胶柱色谱和反相高效液相色谱从烟曲霉F37的培养液中分离得到。在使用大鼠肝微粒体的酶分析系统中，GERI - BP001 M、A和B分别在浓度为42、94和40微摩尔时抑制ACAT活性达50%。